Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Actionable mutations in plasma cell free DNA of Vietnamese patients with non-small cell lung cancer

PROVIDER: PRJNA642002 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12100800.fastq.gz	Fastqsanger.gz
	SRR12100800_1.fastq.gz	Fastqsanger.gz
	SRR12100800_2.fastq.gz	Fastqsanger.gz
	SRR12100900.fastq.gz	Fastqsanger.gz
	SRR12100900_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 791

Similar Datasets

Project description:Plasma cell-free mRNA profiling of Vietnamese Alzheimer's patients

| PRJNA1024653 | ENA

Plasma cell-free DNA methylation profile of patients with non-small cell lung cancer (NSCLC).

Project description:Plasma cell-free DNA methylation profile of patients with non-small cell lung cancer (NSCLC).

| PRJNA1160325 | ENA

Quantitative RT-PCR profiling of miRNA expression of non-small cell lung cancer patients against healthy controls

Project description:Lung cancer (LC) is one of the major cancers, with survival of patients dictated by the time of diagnosis. Cell-free circulating miRNAs have been proposed as candidate biomarkers for non-small cell lung cancer. The goal of this study was to profile the miRNAs in blood plasma of lung cancer patients diagnosed with squamous cell carcinoma (SCC, n=14) or adenocarcinoma (AD, n=6), and healthy individuals (HD) using miRCURY LNA miRNA qPCR Serum/Plasma Panel (Exiqon). Average Cq of detected assays was used for normalization of miRNA expression.

2018-12-30 | E-MTAB-6304 | biostudies-arrayexpress

Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes

Project description:Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes

| PRJNA1006798 | ENA

Plasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer

Project description:Plasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer

| PRJNA963056 | ENA

Plasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer

Project description:The epigenome of plasma cell-free DNA (cfDNA) has demonstrated promise as both a prognostic and predictive cancer biomarker in liquid biopsies. Currently, it remains unknown whether and why cfDNA 5-hydroxymethylcytosine (5hmC) can identify disease state for non-small cell lung cancer (NSCLC). We profiled 5-hydroxymethylomes using the plasma cfDNA of 302 EGFR-mutant NSCLC patients with different disease states. We found NSCLCs were epigenetically heterogeneous among individuals, especially for cfDNA 5hmC on gene EGFR. The diversity of age, sex, race, smoking status, EGFR-mutation of patients increased the epigenetic heterogeneity of NSCLC, however, only smoking status shaped disease state-associated cfDNA 5hmC. More importantly, disease state-dependent and patients’ characteristics-independent cfDNA 5hmC can be linked to lung function and regulatory elements in human lung cells. Interestingly, although 5-hydroxymethylome heterogeneity of plasma cfDNA among NSCLC patients were detected substantially, cfDNA-5hmC-based machine learning model can accurately predict different disease state in NSCLC.

2025-01-29 | GSE231296 | GEO

Gene Amplification Associated Overexpression of the RNA Editing Enzyme ADAR1 Enhances Human Lung Tumorigenesis

Project description:The introduction of new therapies against particular genetic mutations in non-small cell lung cancer is a promising avenue for improving the survival of these patients, but the target population is small. There is a need to uncover new potential actionable genetic lesions and non-conventional cancer pathways, such as RNA editing, are worthy to explore. Herein we show that the adenosine-to-inosine editing enzyme ADAR1 undergoes gene amplification in non-small cancer cell lines and primary tumors in association with higher levels of the corresponding mRNA and protein. From a growth and invasion standpoint, the depletion of ADAR1 expression in amplified cells reduces their tumorigenic potential in cell culture and mice models, whereas its overexpression causes the opposite effects. From a functional perspective, ADAR1 overexpression enhances the editing frequencies of target transcripts such as NEIL1 and miR-381. In the clinical setting, patients with early stage lung cancer, but harboring ADAR1 gene amplification, show poor outcome. Overall, our results indicate a role for ADAR1 as a lung cancer oncogene undergoing gene amplification-associated activation that affect downstream RNA editing patterns and patient prognosis.

2018-04-08 | GSE67660 | GEO

Circulating microRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer

Project description:Plasma samples from 100 early stage (I to IIIA) non–small-cell lung cancer (NSCLC) patients and 100 non-cancer controls were screened for 754 circulating microRNAs via qRT-PCR, using TaqMan MicroRNA Arrays. Our objective was to identify a panel of circulating microRNAs in plasma that will contribute to early detection of lung cancer.

2015-12-31 | GSE64591 | GEO

Homo sapiens

Project description:Differences of actionable genomic alterations between patients with and without hypertension in non-small cell lung cancer

| PRJNA904839 | ENA

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer

Project description:Peripheral blood plasma was collected from unresectable stage III and IV non-small cell lung cancer patients who were negative for driver mutations before receiving immunotherapy. Then we classified samples according to the follow-up results after two courses of immunotherapy and non-targeted metabolomics and proteomics analyses were performed to select different metabolites and proteins. Finally, potential biomarkers were picked out by applying machine learning methods including random forest and stepwise regression and prediction models were constructed by logistic regression.

2024-12-18 | PXD058967 |

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data